ISSN 1662-4009 (online)

ey0017.12-9 | Metabolic Syndrome | ESPEYB17

12.9. Variabilities in childhood cardiovascular risk factors and incident diabetes in adulthood: The Bogalusa Heart Study

T Du , C Fernandez , R Barshop , V Fonseca , W Chen , LA Bazzano

To read the full abstract: Diabetes Care. 2019;42(9):1816–23. doi: 10.2337/dc19-0430Short summary: In this longstanding cohort study (n =1718), high intraindividual variability over time in BMI and in HDL-C during childhood, independent of their mean levels, conferred an increased risk of later-life diabetes.Comment: Intraindividual variabil...

ey0015.11-12 | Hungry fat cells | ESPEYB15

11.12 Asprosin is a centrally acting orexigenic hormone

C Duerrschmid , Y He , C Wang , C Li , JC Bournat , C Romere , PK Saha , ME Lee , KJ Phillips , M Jain , P Jia , Z Zhao , M Farias , Q Wu , DM Milewicz , VR Sutton , DD Moore , NF Butte , MJ Krashes , Y Xu , AR Chopra

To read the full abstract: Nat Med. 2017 Dec; 23(12): 1444–1453This study highlights the importance of asprosin in the regulation of appetite. This peptide hormone was first described by Romere et al. in 2016 (1), who reported 2 patients with neonatal progeroid syndrome (NPS) due to truncating heterozygous mutations in the fibrillin-gene (FBN1). The FBN1 gene encodes profibrillin wh...

ey0016.8-6 | Important for Clinical Practice | ESPEYB16

8.6. Circadian rhythm of glucocorticoid administration entrains clock genes in immune cells: A DREAM trial ancillary study

MA Venneri , V Hasenmajer , D Fiore , E Sbardella , R Pofi , C Graziadio , D Gianfrilli , C Pivonello , M Negri , F Naro , AB Grossman , A Lenzi , R Pivonello , AM Isidori

To read the full abstract: J Clin Endocrinol Metab. 2018; 103(8): 2998–3009.Conventional glucocorticoid (GC) therapy in adrenal insufficiency (AI) does not fully mimic the endogenous cortisol circadian rhythm, and this may adversely affect long-term health. In the recent DREAM trial (Dual Release Hydrocortisone vs. Conventional Glucocorticoid Replacement in H...

ey0017.7-8 | Basic Science | ESPEYB17

7.8. Characterization of the human GnRH neuron developmental transcriptome using a GNRH1-TdTomato reporter line in human pluripotent stem cells

C Lund , V Yellapragada , S Vuoristo , D Balboa , S Trova , C Allet , N Eskici , K Pulli , P Giacobini , T Tuuri , T Raivio

To read the full abstract: Disease Models & Mechanisms vol. 13,3 dmm040105. 13 Mar. 2020. doi: https://dmm.biologists.org/content/13/3/dmm040105.longThese authors developed an in vitro model to study human GnRH neuron transcriptome during developmental differentiation. Gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus govern t...

ey0018.8-6 | Important for Clinical Practice | ESPEYB18

8.6. Reproductive and perinatal outcomes in women with congenital adrenal hyperplasia: A population-based cohort study

AL Hirschberg , S Gidlof , H Falhammar , L Frisen , C Almqvist , A Nordenskjold , A Nordenstrom

J Clin Endocrinol Metab. 2021; 106(2): e957–e965.https://pubmed.ncbi.nlm.nih.gov/33135723/The authors investigated the reproductive and perinatal outcomes in women with congenital adrenal hyperplasia (CAH) compared with control women in the largest such population-based study to date. Women with CAH had lower birth rates, were more likely to develop gestational diabetes, and had other ...

ey0018.11-11 | Criticism of the previous BMI metrics for use in severely obese children | ESPEYB18

11.11. Evaluation of BMI metrics to assess change in adiposity in children with overweight and moderate and severe obesity

SE Barlow , M Salahuddin , C Durand , SJ Pont , DM Hoelscher , NF Butte

Obesity (Silver Spring) 2020 Aug;28(8):1512–1518. https://pubmed.ncbi.nlm.nih.gov/32935936/These authors analysed a cohort of n=399 overweight and obese children (age 2–12 years), who underwent a 1-year lifestyle intervention, to test whether possible alternatives to the BMI z-score (%BMIp95, %BMIp50, BMImz) might correlate better with changes in % total body fat (%BF) a...

ey0020.1-6 | Congenital Hypothyroidism | ESPEYB20

1.6. Effect of initial levothyroxine dose on neurodevelopmental and growth outcomes in children with congenital hypothyroidism

A Esposito , MC Vigone , M Polizzi , MG Wasniewska , A Cassio , A Mussa , R Gastaldi , R Di Mase , G Vincenzi , C Pozzi , E Peroni , C Bravaccio , D Capalbo , D Bruzzese , M Salerno

Brief summary: Current guidelines for congenital hypothyroidism recommend a starting dose of 10–15 μg/d of levothyroxine for optimal treatment (1). Over the last years, some studies suggested that overtreatment of patients during infancy by high levothyroxine doses might have negative effects on neurocognitive and behavioral development (2). The presented multicenter prospective randomized trial aimed at comparing the effect of higher (12.5–15.0 μg/d levoth...

ey0015.8-11 | Clinical Trials – New Treatments | ESPEYB15

8.11 Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial

AM Isidori , MA Venneri , C Graziadio , C Simeoli , D Fiore , V Hasenmajer , E Sbardella , D Gianfrilli , C Pozza , P Pasqualetti , S Morrone , A Santoni , F Naro , A Colao , R Pivonello , A. Lenzi

To read the full abstract: Lancet Diabetes Endocrinol. 2018; 6(3): 173-185Adrenal insufficiency (AI), caused by adrenal failure (primary) or hypothalamo-pituitary failure (secondary), has a prevalence of 250–450 per 1 million (16). AI is potentially life-threatening and requires lifelong glucocorticoid replacement therapy. Modified-release hydrocortisone preparations have bee...

ey0018.9-2 | Cancer treatment and the risk of second neoplasia | ESPEYB18

9.2. Influence of growth hormone therapy on the occurrence of a second neoplasm in survivors of childhood cancer

C Thomas-Teinturier , I Oliver-Petit , H Pacquement , B Fresneau , RS Allodji , C Veres , S Bolle , D Berchery , CHaddy N Demoor-Goldschmidt , I Diallo , F. cecile.teinturier@aphp.fr de Vathaire

Eur J Endocrinol. 2020; 183: 471–480. https://pubmed.ncbi.nlm.nih.gov/32738133/This cohort and nested case–control study analyzed the impact of growth hormone (GH) treatment on the risk of second neoplasm (SN) in a French cohort of 2852 childhood cancer survivors (CCS) treated before 1986. In total, 126 (64.3%) survivors who received GH had been treated for a brain tumor, 22 (11.2...

ey0018.8-1 | Mechanism of the year: neuropeptide substance P regulates aldosterone secretion | ESPEYB18

8.1. The neuropeptide substance P regulates aldosterone secretion in human adrenals

J Wils , C Duparc , AF Cailleux , AG Lopez , C Guiheneuf , I Boutelet , HG Boyer , C Dubessy , S Cherifi , B Cauliez , F Gobet , G Defortescu , JF Menard , E Louiset , H Lefebvre

Nat Commun. 2020;11(1): 2673.https://pubmed.ncbi.nlm.nih.gov/32471973/The authors conducted an experimental study in male human volunteers to examine the effects of a neurokinin type 1 receptor (NK1R) antagonist on aldosterone secretion. The findings show the presence of Substance P (SP)-positive nerve fibres in the human adrenal cortex in the vicinity of aldosterone-producing cells and wit...